***CURRICULUM VITAE***

**Име и Презиме:** Александар Сенев, MD, PhD

**Адреса:** Васко Карангелески 9/1-29, Скопје

**Место на раѓање:** Пробиштип, Северна Македонија

**Националност:** Македонец

***Email*:** [aleksenev@yahoo.com](mailto:aleksenev@yahoo.com)

**Образование:**

**Доктор по медицински науки (PhD)**

Mechanisms of Human Disease, Doctoral School of Biomedical Sciences, Медицински факултет, Католички универзитет во Лувен, Белгија, Мај 2016 – Мај 2020;

**Доктор по медицина (MD)**

Медицински факултет – Скопје, Универзитет Св Кирил и Методиј, 2002 – 2009;

**Гимназија**

ДСУ Наум-Наумовски – Борче, Пробиштип (Северна Македонија), 1998 – 2002;

**Работно Искуство:**

**Научен соработник**

Nephrology and Renal Transplantation Research Group,

Department of Microbiology, Immunology and Transplantation, KU Leuven UZ Herestraat 49, 3000 Leuven (Белгија), Мај 2020 – ;

**Клинички биомедицински експерт**

Laboratory for Histocompatibility and Immunogenetics,

Belgian Red Cross-Flanders, Motstraat 42, Mechelen (Белгија), Април 2016 – ;

**Асистент на Медицински факултет**

Институт за Имунобиологија и Хумана генетика, Медицински факултет – Скопје 2009 – 2019;

**Интернационално истражувачко искуство:**

**Ментор*:* Проф. Др. Anat Roitberg-Tambur**

Transplant Immunology Laboratory, Northwestern University, Chicago, Illinois, USA;Септември – Октомври 2019

**Ментор: Prof. Adrian Liston**

Laboratory of Adaptive Immunity, KU Leuven, Leuven, Belgium;

**Ментор: Prof. An Goris**

Laboratory for Neuroimmunology, KU Leuven, Leuven, Belgium;

September – December 2015

**Членство во интернационални организации:**

European Federation for Immunogenetics (EFI)

European Society for Organ Transplantation (ESOT)

Belgian Transplantation Society (BTS)

American Transplant Society (ATC)

American Society for Histocompatibility and Immunogenetics (ASHI)

**СОФТВЕРСКИ ВЕШТИНИ**

Microsoft Office Work, Excel, PowerPoint.

R, SAS, Graph Pad Prism.

**РЕЦЕНЗЕНТ ВО ИНТЕРНАЦИОНАЛНИ СПИСАНИја**

American journal of Transplantation (IF 7.338),

Frontiers in Immunology (IF 5.085)

Transplantation (IF 4.743)

Transplant international (IF 3.526)

Clinical transplantation (IF 1.665)

**Рецензирани трудови:**

* **Senev, A**., Van Loon, E., Lerut, E., Callemeyn, J., Coemans, M., Van Sandt, V., Kuypers, D., Emonds, M-P., Naesens, M. (2020). Transplant glomerulopathy in the absence of donor-specific HLA antibodies: risk factors, histopathological features and graft outcome. *Kidney International*, accepted manuscript. *(****IF 8.945****)*
* Callemeyn, J., **Senev, A**., Coemans, M., Lerut, E., Sprangers B., Kuypers, D., Koenig A., Thaunat O., Emonds, M-P., Naesens, M. Missing self-induced microvascular rejection of kidney allografts: a population-based study. *J Am Soc Nephrol,* accepted manuscript *(****IF 9.274****)*
* Callemeyn J., Ameye H., Lerut E., **Senev A.,** Coemans M., Van Loon E., Sprangers B., Van Sandt V., Rabeyrin M., Dubois V., Thaunat O., Kuypers D., Emonds M-P, Naesens M. Revisiting the Changes in the Banff Classification for Antibody-Mediated Rejection after Kidney Transplantation. *Am J Transplant*. accepted manuscript *(****IF 7.338****)*
* Vaulet T., Divard G., Thaunat O., Lerut E., **Senev A**., Aubert O., Van Loon E., Callemeyn J., Emonds M-P, Van Craenenbroeck A., De Vusser K., Sprangers B., Rabeyrin M., Dubois V., Kuypers D., De Vos M., Loupy A., De Moor B., Naesens M. Data-driven derivation and validation of novel phenotypes for acute kidney transplant rejection using semi-supervised clustering. *J Am Soc Nephrol*, *(****IF 9.274****)*
* **Senev, A**., Coemans, M., Lerut, E., Van Sandt, V., Kerkhofs, J., Daniëls, L., Driessche, M.V., Compernolle, V., Sprangers, B., Van Loon, E., Callemeyn, J., Claas, F., Tambur, A.R., Verbeke, G., Kuypers, D., Emonds, M-P., Naesens, M. (2020). Eplet Mismatch Load and De Novo Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study. *J Am Soc Nephrol*, 31 (9), 2193-2204. *(****IF 9.274****)*
* Van Loon, E., Lerut, E., **Senev, A**., Coemans, M., Pirenne, J., Monbaliu, D., Jochmans, I., Sainz Barriga, M., De Vusser, K., Van Craenenbroeck, A.H., Sprangers, B., Emonds, M-P., Kuypers, D., Naesens, M. (2020). The Histological Picture of Indication Biopsies in the First 2 Weeks after Kidney Transplantation. *Clin J Am Soc Nephrol*. doi: 10.2215/CJN.04230320 *(****IF 6.628****)*
* **Senev, A**., Otten, H.G., Kamburova, E.G., Callemeyn, J., Lerut, E., Van Sandt, V., Kuypers, D., Emonds, M-P., Naesens, M. (2020). Antibodies Against ARHGDIB and *ARHGDIB Gene* Expression Associate With Kidney Allograft Outcome. *Transplantation*,104(7),1462-1471. *(****IF 4.743****)*
* **Senev, A**., Emonds, M-P., Van Sandt, V., Lerut, E., Coemans, M., Sprangers, B., Kuypers, D., Naesens, M. (2020). Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation. *Am J Transplant*. doi: 10.1111/ajt.15938 *(****IF 7.338****)*
* Daniëls, L., Claas, F.H J., Kramer, C.S M., **Senev, A**., Vanden Driessche, M., Emonds, M-P., Van Laecke, S., Hellemans, R., Abramowicz, D., Naesens, M. (2020). The role of HLA-DP mismatches and donor specific HLA-DP antibodies in kidney transplantation: a case series. *Transpl Immunol*. doi: 10.1016/j.trim.2020.101287 *(****IF 1.624****)*
* Van Loon, E., **Senev, A**., Lerut, E., Coemans, M., Callemeyn, J., Van Keer, J.M., Daniëls, L., Kuypers, D., Sprangers, B., Emonds, M-P., Naesens, M. (2020). Assessing the Complex Causes of Kidney Allograft Loss. *Transplantation*. doi: 10.1097/TP.0000000000003192 *(****IF 4.546****)*
* **Senev, A**., Lerut, E., Van Sandt, V., Coemans, M., Callemeyn, J., Sprangers, B., Kuypers, D., Emonds, M-P., Naesens, M. (2019). Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation. *Am J Transplant*, 19 (11), 3100-3113. doi: 10.1111/ajt.15414 *(****IF 7.338****)*
* Coemans, M., Van Loon, E., Lerut, E., Gillard, P., Sprangers, B., **Senev, A**., Emonds, M-P., Van Keer, J., Callemeyn, J., Daniels, L., Sichien, J., Verbeke, G., Kuypers, D., Mathieu, C., Naesens, M. (2019). Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study. *Diabetes Care*, 42 (4), 625-634. doi: 10.2337/dc18-1936 *(****IF 16.019****)*
* **Senev A.**, Coemans M., Lerut E., Van Sandt V., Daniëls L., Kuypers D., Sprangers B., Emonds M-P., Naesens M. (2019). Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome. *Am J Transplant.* 2019; 19: 763– 780. doi: 10.1111/ajt.15074 *(****IF 7.338****)*
* **Senev A**., Callemeyn J., Lerut E., Emonds M-P., Naesens M. (2019). Histological picture of ABMR without HLA-DSA: Temporal dynamics of effector mechanisms are relevant in disease reclassification. *Am J Transplant*, 19: 954-955. doi: 10.1111/ajt.15234. (***IF 7.338***)
* Kirijas M., Stavrik SG., **Senev A.,** Mladenovska OE., Petlichkovski A. (2018). HLA-A, -B, -C and-DRB1 allele and haplotype frequencies in the Macedonian population based on a family study. *Human Immunology*,79 (3),145-153. doi:10.1016/ j.humimm.2017.12.003; *(****IF 1.95****)*
* Kirijas M., Stavrik SG., Trajkov D., Mitkovska SH., **Senev A.,** Mladenovska OE., Sibinovska O., Petlichkovski A. HLA profile of the donors in the Macedonian Bone Marrow Donor Registry. *Int J Immunogenet*. 2018; 45: 337– 346. doi.org/10.1111/iji.12400; *(****IF 1.079****)*
* **Senev A** and Kocova M. Type 1 diabetes mellitus – review of the immune mechanisms and the genetic background. *Acta morphol.* 2013; Vol.10(1):45-55;
* JakjovskiK, Labachevski N, Petlichkovski A, **Senev A,** Trojacanec J, Atanasovska E, Kostova E, Spiroski M. Distribution ofCYP2C9 and VKORC1 Gene Polymorphisms in Healthy Macedonian Male Population. *Maced J Med Sci.* 2013 Dec 15; 6(4):339-343;
* **Senev A**, Dimitrovski K, Hristova Dimceva A and Petkovska V. HLA sharing among couples with recurrent pregnancy loss in the Republic of Macedonia. *Physioacta.*2013;Vol.7-No.1:45-55;
* Trajkov D, Petlichkovski A, Efinska-Mladenovska O, Hristomanova S, Djulejic E, Kirijas M, **Senev A**, Spiroski M. Distribution of 22 Cytokine Gene Polymorphisms in Roma from the Republic of Macedonia. *Iranian journal of allergy, asthma, and immunology* 12/2012; 11(4):282-293; *(****IF 1.325****)*
* Djulejic E, **Senev A**, Kirijas M,Hristomanova S, Petlichkovski A, Trajkov D, Spiroski M. Allele Frequency of HLA-DQB1 Locus in Macedonian Population. *Maced J Med Sci*. 03/2012;
* Petlichkovski A, Djulejic E, Trajkov D, Efinska-Mladenovska O, Hristomanova S, Kirijas M, **Senev A**, Spiroski M. Distribution of killer cell immunoglobulin-like receptor genes in Roma from Republic of Macedonia. *International Journal of Immunogenetics* 09/2011; 38(6):493-500 *(****IF 1.369****)*
* Hristomanova, S., Grunevska, V., Balabanova-Stefanova, M., Trajkov, D., Petlichkovski, A., Kirijas, M., Djulejic, E., **Senev, A**., Spiroski, M. (2011). Hyper IgE in a HIV positive patient - Case report. *Macedonian Journal of Medical Sciences*, 4 (1), 99-103. doi: 10.3889/MJMS.1857-5773.2011.0160.
* Spiroska V, Kedev S, Antov S, Trajkov D, Petlichkovski A, Hristomanova S, Djulejic E, Paneva M, **Senev A**, Spiroski M. Association between 22 cytokine gene polymorphisms and dilated cardiomyopathy in Macedonian patients. *KardiolPol 2009*; 67: 1237-1247. *(****IF 0.568****)*

**Орални презентации на интернационални конференции:**

* The Impact of HLA-DQ Molecular Mismatches on De Novo Occurrence of Donor-Specific Anti-HLA Antibodies after Kidney Transplantation: An Observational Cohort Study. Presented at *American Transplant Congress (ATC) 2020,* *Virtual Congress*
* Specificity, strength, and evolution of pretransplant donor‐specific HLA antibodies determine outcome after kidney transplantation. Presented at *ASHI/BANFF Join Scientific Meeting 2019, Pittsburgh, PA, USA.*
* Specificity, strength, and evolution of pretransplant donor‐specific HLA antibodies determine outcome after kidney transplantation. Presented at *19th Congress of the European Society for Organ Transplantation (ESOT) 2019, Copenhagen, Denmark.*
* The impact of eplet mismatches on de novo DSA occurrence and graft failure after kidney transplantation. Presented at *19th Congress of the European Society for Organ Transplantation (ESOT) 2019, Copenhagen, Denmark.*
* The impact of eplet mismatches on de novo DSA occurrence and graft failure after kidney transplantation. Presented at *ASHI/BANFF Join Scientific Meeting 2019, Pittsburgh, PA, USA.*
* Extended and high-resolution HLA typing of kidney transplant pairs is necessary to correctly assign donor-specific HLA antibodies prior to solid-organ transplantation. Presented at *19th Congress of the European Society for Organ Transplantation (ESOT) 2019, Copenhagen, Denmark.*
* Transplant glomerulopathy in the absence of donor-specific HLA antibodies: risk factors, histological phenotype and impact on outcome. Presented at *19th Congress of the European Society for Organ Transplantation (ESOT) 2019, Copenhagen, Denmark.*
* Novel non-HLA antibodies against ARHGDIB are associated with kidney allograft failure. Presented at *19th Congress of the European Society for Organ Transplantation (ESOT) 2019, Copenhagen, Denmark.*
* Kinetics of Pretransplant DSA, Post-Transplant Histology, and Graft Failure after Kidney Transplantation. Presented at *American Transplant Congress (ATC) 2019, Boston, USA*.
* Extended and high-resolution HLA typing of the transplant pairs is necessary to correctly assign donor specific HLA antibodies prior solid organ transplantation. Presented at *33rd European Immunogenetics and Histocompatibility Conference (EFI) 2019, Lisbon, Portugal*.
* Phenotype and long-term outcome of the patients with histology of ABMR but without detectable donor-specific HLA antibodies. Presented at the *Joint NTV-BTS Congress 2018, Rotterdam, The Nederland*.
* Development of single molecule real time sequencing of the HLA genome for improved high-resolution HLA genotyping. Presented at *18th Congress of the European Society for Organ Transplantation (ESOT) 2017, Barcelona, Spain*.
* Standard low-resolution HLA genotyping of donors is not sufficient for revealing the risk of severe antibody-mediated kidney allograft rejection. Presented at *18th Congress of the European Society for Organ Transplantation (ESOT) 2017, Barcelona, Spain*.